Our Co-founder, Malcolm Silander, presents at the OBN Awards 2023
Precision BioSearch was delighted to present Jonny Ohlson, Executive Chair and Founder, and Elena Stoyanova, Senior Scientist – New Technologies, of Touchlight with the award for ‘Best Established Biotech Company’ award at the OBN Awards 2023.
The OBN Awards, now in their 15th year, are a highly regarded and sought-after awards programme for the Life Sciences industry, designed to celebrate innovation and outstanding achievement across all corners of the industry.
The twelve award categories shine a light on companies at all stages of development, recognising inspirational leadership, exciting innovation, novel and exciting approaches to unmet clinical needs, outstanding company progression and the delivery of real-life, tangible results. Other finalists for the “Best Established Biotech Company” award included Avacta and Sphere Fluidics.
The Touchlight team enjoyed a pivotal 2023, with the completion of their new GMP manufacturing facility and the progress of enzymatic doggybone DNA (dbDNA) into First-In-Human (FIH) clinical trials in both the US and EU
The OBN Awards, now in their 15th year, are a highly regarded and sought-after awards programme for the Life Sciences industry, designed to celebrate innovation and outstanding achievement across all corners of the industry.
About Touchlight: a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.
For more information, visit: Touchlight
Posted on : 7th Dec 2023